2-(4-氟苯基)胍硝酸盐 | 65783-22-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氟苯基)胍硝酸盐
• 英文名称: (4-fluorophenyl)guanidinium nitrate
• 英文别名: N-(4-fluoro-phenyl)-guanidine nitrate；4-Fluorophenylguanidine nitrate；2-(4-fluorophenyl)guanidine;nitric acid
• CAS: 65783-22-4
• 化学式: C₇H₈FN₃*HNO₃
• 分子量: 216.172
• InChiKey: KTKDJZBVFCEFIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.38
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-氟苯基)胍硝酸盐 生成 4-氟苯胺
  参考文献：
  名称：

  Therapeutic compounds

  摘要：

  本发明提供了式(I)的化合物：其中所有变量如本文所定义，包含这些化合物的药物组合物，制备这些化合物的方法以及它们作为药物代理的用途。

  公开号：

  US20040072853A1
• 作为产物：
  描述：

  氰胺 、 4-氟苯胺 在 硝酸 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以63%的产率得到2-(4-氟苯基)胍硝酸盐
  参考文献：
  名称：

  与钯 (II) 配位的双齿配体的 CH 活化 - 由外部碱基支持的亲电攻击

  摘要：

  2-(2-Phenylaminopyrimidin-4-yl) 吡啶与 (PhCN)2PdCl2 反应时，在苯环胺氮原子邻位发生 C-H 活化，最终形成 N,N,C 配位钯 (II) ) 高产率的配合物。合成了五种不同取代的配合物，并通过光谱学和 X 射线结构分析对其进行了表征。通过动力学实验阐明了形成这些配合物的反应机理，从而可以计算出配合物形成的活化参数。

  DOI：

  10.1002/ejic.201402149

文献信息

• Anti-cancer compounds
  申请人：——

  公开号：US20020019404A1

  公开（公告）日：2002-02-14

  The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

  本发明涉及2-取代的4-杂环芳基嘧啶、其制备、含有它们的药物组合物以及它们作为细胞周期依赖性激酶（CDKs）抑制剂的用途，因此可用于治疗癌症、白血病、牛皮癣等增生性疾病。
• Pyrazolopyridine antiherpetics: SAR of C2′ and C7 amine substituents
  作者：Brian A. Johns、Kristjan S. Gudmundsson、Elizabeth M. Turner、Scott H. Allen、Vicente A. Samano、John A. Ray、George A. Freeman、F. Leslie Boyd、Connie J. Sexton、Dean W. Selleseth、Katrina L. Creech、Kelly R. Moniri

  DOI：10.1016/j.bmc.2005.01.044

  日期：2005.4

  facile access to a diverse set of analogs from common late stage intermediates. Detailed examination of the amine substituents at the C2' position of the pyrimidine and C7 position of the core pyrazolopyridine is described. The antiviral data suggests that non-polar amines are preferred for optimal activity. Additionally, the 2' position has been shown to require an NH group to retain activity levels similar

  已鉴定出一系列新的有效的单纯疱疹病毒1复制的吡唑并[1,5-a]吡啶抑制剂。已开发了几种互补的合成方法，以使从常见的后期中间体容易获得各种类似物。描述了在嘧啶的C2'位置和核心吡唑并吡啶的C7位置上的胺取代基的详细检查。抗病毒数据表明非极性胺是最佳活性的首选。另外，已显示2'位需要一个NH基团以保持与金标准阿昔洛韦相似的活性水平。
• Novel Synthesis of<i>N</i>-Phenyl-2-aminopyrimidine Derivatives under Solvent-Free Conditions
  作者：Ivaylo Elenkov、Davor Kidemet、Vesna Prgomet

  DOI：10.1055/s-2005-917074

  日期：——

  An efficient method for the solvent-free synthesis of N-phenyl-2-aminopyrimidines has been developed through cyclocondensation of N-phenylguanidine with enaminone in the presence of DBU. The procedure is experimentally simple with very short reaction times and good yields. According to this procedure a variety of N-phenyl-2-aminopyrimidines were synthesized.

  通过在DBU存在下，N-苯基胍与烯丙酮环缩合，已开发出一种无溶剂合成N-苯基-2-氨基嘧啶的有效方法。该方法实验简单，反应时间短，收率高。根据该方法，已合成了多种N-苯基-2-氨基嘧啶。
• [EN] N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS<br/>[FR] N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDINE-2-YL) -N-PHENYLAMINES COMME COMPOSES A ACTION ANTIPROLIFERANTE
  申请人：CYCLACEL LTD

  公开号：WO2003029248A1

  公开（公告）日：2003-04-10

  The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

  本发明涉及2-取代的4-杂环芳基嘧啶，它们的制备，包含它们的药物组合物以及它们作为细胞周期依赖性激酶（CDKs）的抑制剂的用途，因此可用于治疗增生性疾病，如癌症、白血病、牛皮癣等。
• [EN] 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS<br/>[FR] 4-HETEROARYLE-PYRIMIDINES SUBSTITUEES EN 2 ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES PROLIFERANTS
  申请人：CYCLACEL LTD

  公开号：WO2001072745A1

  公开（公告）日：2001-10-04

  The present invention relates to 2-substituted 4-heteroaryl-pyrimidines,(Fig.I), wherein: X1 is CH and X2 is S; or one of X?1 and X2¿ is S, and the other of X?1 and X2¿ is N; Z is NH, NHCO, NHSO¿2?, NHCH2, CH2, CH2CH2, or CH=CH; R?1, R2 and R3¿ are independently H, alkyl, aryl, aralkyl, heterocycle, halogeno, NO¿2?, CN, OH, alkoxy, aryloxy, NH2, NH-R', N-(R')(R''), NH-COR', NH-aryl, N-(aryl)2, COOH, COO-R', COO-aryl, CONH2, CONH-R', CON-(R')(R''),CONH-aryl, CON-(aryl)2, SO3H, SO2NH2, CF3, CO-R', or CO-aryl, wherein alkyl, aryl, aralkyl, heterocycle and NH-aryl groups may be further substituted with one or more groups selected from halogeno, NO2, CN, OH, O-methyl, NH2, COOH, CONH2 and CF3; at least one of the groups R?1 and R2¿ being other than H when either X1 or X2 is S; R?4, R5, R6, R7 and R8¿ are independently from each other H, substituted or unsubstituted lower alkyl, halogeno, NO¿2?, CN, OH, substituted or unsubstituted alkoxy, NH2, NH-R', alkyl-aryl, alkyl-heteroaryl, NH(C=NH)NH2, N(R')3?+¿, N(R')(R''), COOH, COO-R', CONH¿2?, CONH-R', CON-(R')(R''), SO3H, SO2NH2, CF3 or (CH2)nO(CH2)m NR'R'', (CH2)nCO2(CH2)mOR''' wherein n is 0,1,2 or 3 and m is 1, 2 or 3; their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependant kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

  本发明涉及2-取代的4-杂环芳基嘧啶（图I），其中：X1为CH，X2为S；或X1和X2中的一个为S，另一个为N；Z为NH，NHCO，NHSO2，NHCH2，CH2，CH2CH2或CH=CH；R1，R2和R3独立地为H，烷基，芳基，芳基烷基，杂环，卤代，NO2，CN，OH，烷氧基，芳氧基，NH2，NH-R'，N-(R')(R'')，NH-COR'，NH-芳基，N-(芳基)2，COOH，COO-R'，COO-芳基，CONH2，CONH-R'，CON-(R')(R'')，CONH-芳基，CON-(芳基)2，SO3H，SO2NH2，CF3，CO-R'或CO-芳基，其中烷基，芳基，芳基烷基，杂环和NH-芳基基团可以进一步取代为卤代，NO2，CN，OH，O-甲基，NH2，COOH，CONH2和CF3中的一种或多种基团；当X1或X2为S时，R1和R2中至少有一个不为H；R4，R5，R6，R7和R8独立地为H，取代或未取代的低级烷基，卤代，NO2，CN，OH，取代或未取代的烷氧基，NH2，NH-R'，烷基-芳基，烷基-杂环芳基，NH(C=NH)NH2，N(R')3+，N(R')(R'')，COOH，COO-R'，CONH2，CONH-R'，CON-(R')(R'')，SO3H，SO2NH2，CF3或(CH2)nO(CH2)mNR'R''，其中n为0，1，2或3，m为1，2或3；它们的制备，包含它们的制药组合物以及它们作为细胞周期依赖性激酶（CDK）的抑制剂的用途，因此在治疗增生性疾病，如癌症，白血病，牛皮癣等方面使用。